PBYI

MKT CAP:$382M

Puma Biotechnology, Inc.

Market Cap

$382M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$7.40+$1.63 (+28.25%)

Apr 23, 2026

Company Details

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral...

CEO

Alan H. Auerbach

IPO Date

Apr 24, 2012

Website

www.pumabiotechnology.com

Key Metrics TTM

Revenue

$212M

-13.0% YoY

Net Income

$37M

EPS (Diluted)

$0.74

Free Cash Flow

$43M

Revenue / Share

$4.16

Gross Margin

76.9%

Operating Margin

15.8%

Net Margin

17.4%

FCF Margin

20.2%

P/S

1.8x

P/E

10.3x

Earnings Reports

Q4 2025

May 14, 2026

PENDING

FY 2025

Feb 26, 2026

$228M-0.9%EPS $0.61

Q3 2025

Nov 6, 2025

$54M-32.4%EPS $0.17

Q2 2025

Aug 7, 2025

$52M+11.4%EPS $0.12

Q1 2025

May 8, 2025

$46M+5.1%EPS $0.06

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$55M	$43M	-$24M
Q1 22	$46M	$35M	-$747.0K
Q2 22	$60M	$45M	$12M
Q3 22	$57M	$45M	$2M
Q4 22	$66M	$49M	$10M
Q1 23	$53M	$40M	$4M
Q2 23	$55M	$43M	$5M
Q3 23	$56M	$43M	$9M
Q4 23	$72M	$48M	$15M
Q1 24	$44M	$33M	-$2M
Q2 24	$47M	$36M	-$2M
Q3 24	$81M	$51M	$22M
Q4 24	$59M	$45M	$13M
Q1 25	$46M	$35M	$4M
Q2 25	$52M	$40M	$7M
Q3 25	$54M	$42M	$10M

Valuation

Quarter	P/S	P/E
Q4 21	1.5x	—
Q1 22	1.6x	—
Q2 22	1.8x	—
Q3 22	1.8x	38.8x
Q4 22	1.7x	190786.8x
Q1 23	1.6x	79.4x
Q2 23	1.7x	—
Q3 23	1.7x	102.7x
Q4 23	1.6x	17.7x
Q1 24	1.7x	24.8x
Q2 24	1.7x	43.8x
Q3 24	1.6x	16.4x
Q4 24	1.7x	12.6x
Q1 25	1.6x	10.0x
Q2 25	1.6x	7.9x
Q3 25	1.8x	10.3x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$5M	-$5M
Q1 22	-$27M	-$27M
Q2 22	-$14M	-$14M
Q3 22	$17M	$17M
Q4 22	$8M	$683.0K
Q1 23	$3M	-$10M
Q2 23	$3M	$3M
Q3 23	$11M	$11M
Q4 23	$10M	$10M
Q1 24	$11M	$11M
Q2 24	$1M	$1M
Q3 24	$11M	$11M
Q4 24	$16M	$16M
Q1 25	$4M	$4M
Q2 25	$14M	$14M
Q3 25	$10M	$10M

Capital Expenditures

Quarter	CapEx
Q4 21	$0
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$7M
Q1 23	$13M
Q2 23	$68.0K
Q3 23	$27.0K
Q4 23	$45.0K
Q1 24	$0
Q2 24	$20.0K
Q3 24	$20.0K
Q4 24	$16.0K
Q1 25	$61.0K
Q2 25	$20.0K
Q3 25	$26.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	+9.1%	+25.5%
Q1 22	-13.0%	-27.0%
Q2 22	-39.4%	-39.2%
Q3 22	+23.5%	-0.9%
Q4 22	+18.6%	-29.5%
Q1 23	+15.4%	+4.1%
Q2 23	-8.3%	+4.7%
Q3 23	-1.7%	-13.1%
Q4 23	+9.9%	+3.1%
Q1 24	-17.1%	-4.8%
Q2 24	-13.7%	-0.8%
Q3 24	+43.5%	+23.0%
Q4 24	-18.2%	-20.3%
Q1 25	+5.1%	-8.8%
Q2 25	+11.4%	-7.0%
Q3 25	-32.4%	-23.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$4M	7.7%
Q1 22	$3M	6.9%
Q2 22	$3M	5.4%
Q3 22	$3M	5.0%
Q4 22	$3M	4.0%
Q1 23	$3M	5.4%
Q2 23	$2M	4.5%
Q3 23	$3M	4.5%
Q4 23	$2M	3.4%
Q1 24	$2M	5.4%
Q2 24	$2M	4.4%
Q3 24	$2M	2.6%
Q4 24	$2M	3.0%
Q1 25	$2M	4.4%
Q2 25	$2M	3.1%
Q3 25	$2M	3.1%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 21	$14M	$22M	—	—
Q1 22	$15M	$20M	—	—
Q2 22	$12M	$21M	—	—
Q3 22	$11M	$24M	—	—
Q4 22	$14M	$25M	—	—
Q1 23	$13M	$22M	—	—
Q2 23	$13M	$24M	—	—
Q3 23	$11M	$22M	—	—
Q4 23	$13M	$20M	$367.0K	—
Q1 24	$14M	$22M	$110.0K	—
Q2 24	$14M	$25M	—	—
Q3 24	$13M	$17M	—	—
Q4 24	$15M	$17M	—	—
Q1 25	$14M	$17M	—	—
Q2 25	$15M	$18M	—	—
Q3 25	$16M	—	—	$17M

Revenue Segments

Quarter	Product	Royalty
Q1 22	$41M	$5M
Q2 22	$51M	$8M
Q3 22	$54M	$3M
Q4 22	$54M	$12M
Q1 23	$47M	$6M
Q2 23	$52M	$3M
Q3 23	$52M	$5M
Q4 23	$53M	$19M
Q1 24	$40M	$3M
Q2 24	$44M	$3M
Q3 24	$56M	$24M
Q1 25	$43M	$3M
Q2 25	$49M	$3M
Q3 25	$52M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$64M	$10M	$74M
Q2 22	$53M	$8M	$61M
Q3 22	$78M	$0	$78M
Q4 22	$76M	$5M	$81M
Q1 23	$61M	$10M	$71M
Q2 23	$60M	$14M	$74M
Q3 23	$82M	$3M	$85M
Q4 23	$85M	$11M	$96M
Q1 24	$77M	$30M	$107M
Q2 24	$67M	$30M	$97M
Q3 24	$67M	$29M	$97M
Q4 24	$69M	$32M	$101M
Q1 25	$63M	$30M	$93M
Q2 25	$55M	$41M	$96M
Q3 25	$54M	$41M	$94M
Q4 25	$30M	$68M	$98M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	41M	+0.6%	+3.4%
Q1 22	42M	+2.8%	+5.8%
Q2 22	45M	+7.5%	+10.9%
Q3 22	46M	+0.5%	+11.6%
Q4 22	46M	+0.5%	+11.6%
Q1 23	47M	+2.9%	+11.7%
Q2 23	47M	+0.1%	+4.1%
Q3 23	48M	+1.3%	+4.9%
Q4 23	48M	+0.5%	+4.9%
Q1 24	48M	+0.3%	+2.2%
Q2 24	48M	+0.2%	+2.3%
Q3 24	49M	+1.8%	+2.8%
Q4 24	49M	+0.5%	+2.8%
Q1 25	50M	+1.0%	+3.6%
Q2 25	50M	+0.5%	+3.8%
Q3 25	51M	+1.6%	+3.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$282.4K	196
Q1 22	$233.3K	196
Q2 22	$303.7K	196
Q3 22	$291.3K	196
Q4 22	$342.1K	192
Q1 23	$274.9K	192
Q2 23	$284.2K	192
Q3 23	$292.3K	192
Q4 23	$390.2K	185
Q1 24	$236.6K	185
Q2 24	$254.5K	185
Q3 24	$435.4K	185
Q4 24	$343.5K	172
Q1 25	$267.5K	172
Q2 25	$304.9K	172
Q3 25	$316.7K	172

Revenue / Employee